853299-52-2

Upstream product

• 654-70-6 4-amino-2-trifluoromethylbenzonitrile 
• 876322-73-5 4-amino-2-(trifluoromethyl)benzaldehyde 
• 630125-91-6 4-(4-ethylpiperazin-1-ylmethyl)-3-trifluoromethylphenylamine 
• 417724-26-6 4-(4-amino-phenoxy)-pyrimidin-2-ylamine 
• 54840-15-2 4-N-tert-butoxycarbonylaminophenol 
• 630125-92-7 N-[4-(4-ethyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-2,2,2-trifluoro-acetamide 
• 853298-46-1 4-(4-nitro-phenoxy)-pyrimidin-2-ylamine 

Relevant academic research and scientific papers

Syntheses of a triad of Flt3 kinase inhibitors: From bench to pilot plant

We have designed and developed an alternative synthesis for the manufacturing of a triad of Flt3 kinase inhibitors (AST487, ATH686, and AUZ454) to support clinical assessments of patients with Flt3-dependent tumor diseases. The new synthesis is convergent

DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES

The invention relates to the use of diaryl urea derivatives for the manufacture of pharmaceutical compositions for the treatment of RET dependent disorders, especially RET dependent tumor diseases. The invention further relates to novel N-[4-(pyrimidin-4-yloxy)-phenyl]-N’-phenyl-urea derivatives and their use in the treatment of the animal or human body, especially in the treatment of a protein kinase dependent disease, to pharmaceutical compositions comprising such novel N-[4-pyrimidin-4-yloxy)-phenyl]-N’-phenyl-urea derivatives and to the use of such novel N-[4-(pyrimidin-4-yloxy)-phenyl]-N’-phenyl-urea derivatives for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as tumour diseases.